Evaluation of transurethral application of alprostadil for erectile dysfunction in Indonesians

作     者：Wimpie I.Pangkahila 

作者机构：Department of Reproductive Medicine Udayana University Denpasar Indonesia 

出 版 物：《Asian Journal of Andrology》 (亚洲男性学杂志（英文版）)

年 卷 期：2000年第2卷第3期

页      面：233-236页

核心收录：

学科分类：1002[医学-临床医学] 100210[医学-外科学(含：普外、骨外、泌尿外、胸心外、神外、整形、烧伤、野战外)] 10[医学] 

主　　题：erectile dysfunction alprostadil transurethral application 

摘      要：Aim: To evaluate the efficacy and safety of transurethral application of alprostadil (MUSE^(R) ) for the treatment oferectile dysfunction in Indonesians. Methods: Twenty erectile dysfunction patients aged between 32-74 years oldwere recruited in this study. The inclusion criteria were as follows: 1) adult males 18 years or older with a subjectivecomplaint or erectile dysfunction, 2) to provide written informed consent, 3) to agree not to use other forms of treat-ment for erectile dysfunction, 4) fulfill the screening laboratory values. Part Ⅰ, eligible patients were titrated in theclinic starting with a dose of 250μg and proceed in a stepwise manner to 500 μg and 1000 μg on separate clinic visitsuntil they identified a dose that produced a satisfactory response. The interval between each in-clinic titration was 2-3days. Each in-clinic titration dose was evaluated at 15 rain intervals over a one hour period for erection assessment,blood pressure and pulse. Part 2, patients used MUSE at home for three months at the dose identified during the in-clinic titration. Monthly interim visits were required for patient follow-up and drug distribution. At the end of thestudy, patients had another laboratory (except testosterone, only assayed in screening procedure) and physical examina-tion. Results: The etiology of erectile dysfunction was psychological in 5 patients and organic in 15 patients. The65% of the patients achieved the erection scale of 4 or 5 either in the clinic or at home, 10% achieved the scale of 4at home, but not in the clinic, and 25% only achieved the scale of 2 or 3 with the highest dose of 1000 μg either in theclinic or at home. No significant differences were found in biochemical examination before and after the study. The60% of the patients who achieved erection scale 4 or 5 continued to use MUSE until the end of the study, while 40%of them complained of pain at the time of MUSE application, during erection and/or during intercourse. They withdrewfrom th